Regeneus
Pymble
About Regeneus
Founded in 2007, they are a Sydney-based regenerative medicine company developing a portfolio of innovative cell-based therapies targeting unmet medical needs in human, with an initial focus on osteoarthritis (OA), neuropathic pain and dermatology. All of the products in their pipeline are underpinned by proprietary stem cell technologies. Regeneus listed on the Australian Stock Exchange (ASX: RGS) in September 2013. Regenerative medicine is a rapidly advancing interdisciplinary field in healthcare that focuses on repairing and regenerating cells, tissues and organs with the goal to enhance the body’s natural ability to replace or repair tissue damaged or destroyed by injury or disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2021)
- Ticker: asx:RGS
- Website: regeneus.com.au
- Phone: +61 2 9499 8010
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/regeneus-2183692 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.